InVivo Therapeutics Stock Forecast, Price & News

-0.01 (-1.62 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume337,393 shs
Average Volume2.46 million shs
Market Capitalization$20.85 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

InVivo Therapeutics logo

About InVivo Therapeutics

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.08 out of 5 stars

Medical Sector

1199th out of 1,352 stocks

Surgical & Medical Instruments Industry

116th out of 123 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

InVivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What stocks does MarketBeat like better than InVivo Therapeutics?

Wall Street analysts have given InVivo Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InVivo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InVivo Therapeutics?

InVivo Therapeutics saw a decrease in short interest in the month of July. As of July 30th, there was short interest totaling 2,590,000 shares, a decrease of 23.1% from the July 15th total of 3,370,000 shares. Based on an average daily trading volume, of 854,400 shares, the short-interest ratio is presently 3.0 days. Currently, 8.3% of the company's shares are sold short.
View InVivo Therapeutics' Short Interest

When is InVivo Therapeutics' next earnings date?

InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for InVivo Therapeutics

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) EPS for the quarter.
View InVivo Therapeutics' earnings history

How has InVivo Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

InVivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVIV stock has decreased by 62.0% and is now trading at $0.6086.
View which stocks have been most impacted by COVID-19

When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?

InVivo Therapeutics shares reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Who are InVivo Therapeutics' key executives?

InVivo Therapeutics' management team includes the following people:
  • Richard Toselli, President, Chief Executive Officer & Director
  • William D'Agostino, Senior Vice President-Operations
  • Richard C. Christopher, Chief Financial Officer & Treasurer
  • Heather Hamel, Secretary, VP-Legal Affairs & Business Development

Who are some of InVivo Therapeutics' key competitors?

What other stocks do shareholders of InVivo Therapeutics own?

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are InVivo Therapeutics' major shareholders?

InVivo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.55%), Geode Capital Management LLC (0.81%), State Street Corp (0.64%), Morgan Stanley (0.15%), Morgan Stanley (0.15%) and Goldman Sachs Group Inc. (0.12%).
View institutional ownership trends for InVivo Therapeutics

Which institutional investors are buying InVivo Therapeutics stock?

NVIV stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Geode Capital Management LLC, Morgan Stanley, Morgan Stanley, and Goldman Sachs Group Inc..
View insider buying and selling activity for InVivo Therapeutics
or or view top insider-buying stocks.

How do I buy shares of InVivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $0.61.

How much money does InVivo Therapeutics make?

InVivo Therapeutics has a market capitalization of $20.85 million.

How many employees does InVivo Therapeutics have?

InVivo Therapeutics employs 6 workers across the globe.

What is InVivo Therapeutics' official website?

The official website for InVivo Therapeutics is

Where are InVivo Therapeutics' headquarters?

InVivo Therapeutics is headquartered at ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 863-5500 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.